Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug

Journal of Allergy and Clinical Immunology

Volumn 110, Issue 2, 2002, Pages 277-284

  Kapp, Alexander ^a   Papp, Kim ^b   Bingham, Ann ^c   Fölster Holst, Regina ^d   Ortonne, Jean Paul ^e   Potter, Paul C ^f   Gulliver, Wayne ^g   Paul, Carle ^h   Molloy, Stephen ^h   Barbier, Nathalie ^h   Thurston, Mark ^h   De Prost, Yves ⁱ   Moor, A De ^j   Mehra, S ^j   Tan, J ^j   Escande, J P ^j   Bonerandi, J J ^j   Ruer Mulard, M ^j   Schill, W B ^j   Meurer, M ^j   Schauer, U ^j   Hofmann, H ^j   Scheer, T ^j   Birchall, N ^j   Oakley, A ^j   Green, R ^j   Jacovides, J A ^j   Manjra, A ^j   Raboobee, N ^j   Walele, A ^j   Reyneke, S J ^j   Puig, L ^j   Bingham, A ^k   Darrah, A ^k   McKinnon, C ^k   Sarin, R ^k   Garala, M ^k   Young, K ^k   Barnard, S ^k   Thompson, R ^k   Weaver, A ^k   Smith, C ^k   Marazzi, P ^k   Martin, R ^k   Allamby, P ^k   Gooding, T ^k   Goertz, Hans Peter ^h   Langlo, F ^h   Metivier, B ^h   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Probity Medical Research   (Belgium)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g NewLab Clinical Research   (Canada)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j NONE   (Spain)

^k Groupe Hospitalier Necker Enfants Malades   (United Kingdom)

more..

Author keywords

Atopic dermatitis; Eczema; Elidel; Long term management; Pimecrolimus; SDZ ASM 981

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PIMECROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HUMAN; INCIDENCE; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN INFECTION; SYMPTOM; VIRUS INFECTION;

EID: 0036677154     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.126500     Document Type: Article

References (33)

1. Atopic dermatitis - The skin manifestation of atopy
2. Atopic dermatitis and allergic contact dermatitis
3. The epidemiology of atopic dermatitis
4. Prevalence of atopic eczema in children between 0 and 30 months on Avon district
5. The prevalence of childhood atopic eczema in a general population
6. Topical steroid treatment in infants, children, and adolescents
7. Managing pediatric atopic dermatitis
8. Incidence and degree of unwanted adverse effects of corticoids in childhood: Results of dermatological studies in children with chronic diseases in the age group of 1-15 years
9. Adverse effects from topical steroids
10. Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment
11. Cushing's syndrome after topical application of corticosteroids
12. Dwarfism following long-term topical corticosteroid therapy
13. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood
14. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
15. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner
16. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
17. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study
18. Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis
19. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents
20. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis
21. A new approach to the analysis of clinical drug trials with withdrawals
22. Non parametric estimation from incomplete samples
23. Systematic review of treatments for atopic eczema
24. The infants' dermatitis quality of life index
25. Systemic side-effects of topical preparation in children
26. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease
27. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children
28. Minimising the use of topical steroids in children
29. Topical corticosteroid phobia in patients with atopic eczema
30. Compliance problems in pediatric atopic eczema
31. Why do patients with atopic dermatitis refuse to apply topical corticosteroids?
32. First experience of topical SDZ ASM 981 in children with atopic dermatitis